Medication orlistat appears helpful in improving weight management for obese adolescents

June 14, 2005

When combined with diet, exercise and behavioral therapy, orlistat, a drug that decreases fat absorption, appears helpful for improving weight management in obese adolescents, compared with placebo, according to an article in the June 15 issue of JAMA.

Excess weight in adolescents is associated with increased risk of hyperlipidemia and type 2 diabetes, and its prevalence is increasing worldwide, according to background information in the article. In the United States, the proportion of adolescents with a body mass index (BMI) at or above the 95th percentile for age, a widely accepted definition of obesity in adolescents, has increased 15.5 percent to 23.4 percent in certain ethnic minorities. Overweight children are at a 15-fold greater risk of becoming overweight adults compared to children and adolescents not overweight. Pediatric obesity can be particularly difficult to treat, with long-term success depending on the type of therapy used. Orlistat is a gastrointestinal tract lipase (an enzyme) inhibitor which decreases intestinal fat absorption by up to 30 percent; in adults, the drug has a good safety profile and is generally well tolerated.

Jean-Pierre Chanoine, M.D., Ph.D., from the British Columbia Children's Hospital, Vancouver, and colleagues examined the effectiveness and safety of orlistat for weight management in adolescents, in this 54-week, randomized, double-blind study. Participants were aged 12 to 16 years and had a BMI (calculated as weight in kilograms divided by the square of height in meters) two units or more above the 95th percentile at baseline. Three hundred fifty-seven patients received 120 mg of orlistat three times daily and 182 participants received placebo three times daily for one year. Both groups were given instructions on how to maintain a reduced calorie diet, and received counseling for exercise and behavior modification (i.e., recording food intake, recognizing cues for overeating). The researchers also assessed the impact of orlistat treatment on waist circumference, lipid levels, blood pressure, and glucose and insulin.

The researchers found that both groups experienced a decrease in BMI up to week 12, thereafter stabilizing with orlistat but increasing beyond baseline with placebo. At the end of the study, BMI had decreased by 0.55 with orlistat, and had increased by 0.31 with placebo; weight had increased 0.53 kg. with orlistat and 3.14 kg. with placebo. At the study's end, 15.7 percent of the placebo group compared to 26.5 percent of orlistat patients had a five percent or higher decrease in BMI, and 4.5 percent of the placebo group and 13.3 percent of the orlistat group had a ten percent or higher decrease in BMI.

Waist circumference also decreased in the orlistat group by 1.33 cm (.52 inches) and increased by .12 cm (.047 inches) in the placebo group. Mild to moderate gastrointestinal tract adverse effects (such as nausea, fatty/oily stools, and abdominal pain) occurred in 9 percent to 50 percent of the orlistat group, and one percent to 13 percent of the placebo group.

"We conclude that treatment with 120 mg of orlistat three times daily for 52 weeks, in conjunction with a reduced-calorie diet, exercise, and behavioral modification, statistically significantly improves weight management in obese adolescent participants," the authors write. "This effect is probably due to the decrease in the absorption of fat and its associated calories."

(JAMA. 2005; 293:2873 - 2883. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Notes: This study was funded by F. Hoffmann-La Roche Ltd. Dr. Chanoine has received honoraria from Hoffmann-La Roche for speakers presentations. No other authors reported financial disclosures.

Editorial: Pharmacotherapy for Adolescent Obesity - A Weighty Issue

In an accompanying editorial, Alain Joffe, M.D., M.P.H., from Johns Hopkins University, Baltimore, writes "Until public health efforts to prevent child and adolescent obesity are developed and successfully implemented on a broad scale, physicians are likely to encounter significant numbers of obese adolescents for the foreseeable future. ... appropriate management of this chronic health condition is a pressing but daunting task for physicians."

"Obesity is by nature a chronic disease. Many obese individuals who lose weight regain it over time, often exceeding their original weight," Dr. Joffe writes. "What will be critical to determine is whether the weight loss (or slowing of weight gain) achieved by those treated with orlistat is sustainable over time. Once adolescents stop using orlistat, will they maintain their weight loss, or will maintenance required ongoing use of the medication?"

He concludes by saying "It would not be surprising that no single weight-loss medication will find favor with all adolescents; pharmacotherapy will need to be individualized following a comprehensive assessment of the adolescent including the presence or absence of various comorbidities [related disease]. ... Until [more] data are available, use of orlistat should be limited to settings that offer comprehensive assessment and management of obese adolescents. There is no justification for using it as a stand-alone treatment.
-end-
(JAMA. 2005; 293: 2932 - 2934. Available pre-embargo to the media at www.jamamedia.org.)

The JAMA Network Journals

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.